OMEROS CORP Deferred Income Tax Expense (Benefit)
OMEROS CORP (OMER) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-31
- OMEROS CORP deferred income tax expense (benefit) for the quarter ending 2020-12-31 was -$15.40M.
- OMEROS CORP deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- OMEROS CORP deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- OMEROS CORP deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- OMEROS CORP deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-31 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-31 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-04-01 | |||
| 2020-12-31 | -$15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$23.26M 10-K · filed 2023-03-13 | -$12.01M 10-K · filed 2021-03-01 | |
| 2020-09-30 | -$7.85M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | -$19.77M 10-K · filed 2022-03-01 | $0.00 10-K · filed 2020-03-02 | ||
| 2018-12-31 | -$12.93M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |